{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:20:56Z","timestamp":1790806856932,"version":"4.1.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01EY021137"],"award-info":[{"award-number":["R01EY021137"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aaojournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.ophtha.2020.12.028","type":"journal-article","created":{"date-parts":[[2020,12,30]],"date-time":"2020-12-30T20:22:06Z","timestamp":1609359726000},"page":"1188-1196","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["Retinal Detachment after Treatment of Retinopathy of Prematurity with Laser versus Intravitreal Anti\u2013Vascular Endothelial Growth Factor"],"prefix":"10.1016","volume":"128","author":[{"given":"Gerard P.","family":"Barry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3820-1257","authenticated-orcid":false,"given":"Yinxi","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gui-Shuang","family":"Ying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren A.","family":"Tomlinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliann","family":"Lajoie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0042-8077","authenticated-orcid":false,"given":"Marilyn","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3633-2114","authenticated-orcid":false,"given":"Gil","family":"Binenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ophtha.2020.12.028_bib1","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2018-3061","article-title":"Screening Examination of Premature Infants for Retinopathy of Prematurity","volume":"142","author":"Fierson","year":"2018","journal-title":"Pediatrics"},{"issue":"12","key":"10.1016\/j.ophtha.2020.12.028_bib2","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","article-title":"Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial","volume":"121","year":"2003","journal-title":"Arch Ophthalmol"},{"issue":"9","key":"10.1016\/j.ophtha.2020.12.028_bib3","doi-asserted-by":"crossref","first-page":"486","DOI":"10.3928\/23258160-20200831-02","article-title":"Two-year outcomes comparing anti-VEGF injections to laser for ROP using a commercial claims database","volume":"51","author":"Zhang","year":"2020","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"7","key":"10.1016\/j.ophtha.2020.12.028_bib4","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.ophtha.2020.12.028_bib5","first-page":"260","article-title":"Short-term retinal detachment risk after treatment of type 1 retinopathy of prematurity with laser photocoagulation versus intravitreal bevacizumab","volume":"23","author":"Barry","year":"2019","journal-title":"J\u00a0AAPOS"},{"issue":"1","key":"10.1016\/j.ophtha.2020.12.028_bib6","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1001\/jamaophthalmol.2019.4517","article-title":"Validation of the postnatal growth and retinopathy of prematurity screening criteria","volume":"138","author":"Binenbaum","year":"2019","journal-title":"JAMA Ophthalmol"},{"issue":"9","key":"10.1016\/j.ophtha.2020.12.028_bib7","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1001\/jamaophthalmol.2018.2753","article-title":"Development of modified screening criteria for retinopathy of prematurity","volume":"136","author":"Binenbaum","year":"2018","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"10.1016\/j.ophtha.2020.12.028_bib8","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1080\/09286586.2016.1255765","article-title":"Postnatal growth and retinopathy of prematurity study: rationale, design, and subject characteristics","volume":"24","author":"Binenbaum","year":"2017","journal-title":"Ophthalmic Epidemiol"},{"issue":"1","key":"10.1016\/j.ophtha.2020.12.028_bib9","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1080\/00031305.1983.10483087","article-title":"A\u00a0leisurely look at the bootstrap, the jackknife, and cross-validation","volume":"37","author":"Efron","year":"1983","journal-title":"Am Stat"},{"issue":"12","key":"10.1016\/j.ophtha.2020.12.028_bib10","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","article-title":"Revised indications for the treatment of retinopathy of prematurity: results of the Early Treatment for Retinopathy of Prematurity Randomized Trial","volume":"121","year":"2003","journal-title":"Arch Ophthalmol"},{"issue":"9","key":"10.1016\/j.ophtha.2020.12.028_bib11","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1001\/archophthalmol.2011.229","article-title":"Outcome of eyes developing retinal detachment during the Early Treatment for Retinopathy of Prematurity Study","volume":"129","author":"Repka","year":"2011","journal-title":"Arch Ophthalmol"},{"issue":"3","key":"10.1016\/j.ophtha.2020.12.028_bib12","first-page":"365","article-title":"Treatment of type I ROP with intravitreal bevacizumab or laser photocoagulation according to retinal zone","volume":"101","author":"Mueller","year":"2017","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"10.1016\/j.ophtha.2020.12.028_bib13","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/ICB.0000000000000794","article-title":"Short-term computer-assisted quantification of plus disease after treatment of\u00a0type 1 retinopathy of with intravitreal bevacizumab or retinal laser photocoagulation","volume":"15","author":"Cabrera","year":"2021","journal-title":"Retin Cases Brief Rep"},{"issue":"5","key":"10.1016\/j.ophtha.2020.12.028_bib14","first-page":"264","article-title":"Aggressive posterior retinopathy of prematurity in two cohorts of patients in South India: implications for primary, secondary, and tertiary prevention","volume":"23","author":"Shah","year":"2019","journal-title":"J\u00a0AAPOS"},{"issue":"11","key":"10.1016\/j.ophtha.2020.12.028_bib15","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/S0161-6420(91)32074-8","article-title":"Incidence and early course of retinopathy of prematurity. The Cryotherapy for Retinopathy of Prematurity Cooperative Group","volume":"98","author":"Palmer","year":"1991","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.ophtha.2020.12.028_bib16","first-page":"61","article-title":"Comparison of intravitreal bevacizumab injection and laser photocoagulation for type 1 zone II retinopathy of prematurity","volume":"31","author":"Roohipoor","year":"2019","journal-title":"J\u00a0Curr Ophthalmol"},{"issue":"1","key":"10.1016\/j.ophtha.2020.12.028_bib17","doi-asserted-by":"crossref","first-page":"29","DOI":"10.4103\/jovr.jovr_198_16","article-title":"Efficacy of intravitreal bevacizumab for the treatment of zone I type 1 retinopathy of prematurity","volume":"13","author":"Karkhaneh","year":"2018","journal-title":"J\u00a0Ophthalmic Vis Res"},{"issue":"1","key":"10.1016\/j.ophtha.2020.12.028_bib18","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/IAE.0000000000001125","article-title":"Outcomes after laser versus combined laser and bevacizumab treatment for type 1 retinopathy of prematurity in zone I","volume":"37","author":"Yoon","year":"2017","journal-title":"Retina"},{"issue":"7","key":"10.1016\/j.ophtha.2020.12.028_bib19","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1001\/archopht.123.7.991","article-title":"The International Classification of Retinopathy of Prematurity revisited","volume":"123","year":"2005","journal-title":"Arch Ophthalmol"},{"issue":"8","key":"10.1016\/j.ophtha.2020.12.028_bib20","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1016\/j.ophtha.2016.04.035","article-title":"Diagnostic discrepancies in retinopathy of prematurity classification","volume":"123","author":"Campbell","year":"2016","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.ophtha.2020.12.028_bib21","first-page":"128","article-title":"Ocular complications following treatment in the Postnatal Growth and Retinopathy of Prematurity (G-ROP) Study","volume":"22","author":"Morrison","year":"2018","journal-title":"J\u00a0AAPOS"},{"key":"10.1016\/j.ophtha.2020.12.028_bib22","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2147\/EB.S189684","article-title":"Evidence to date: ranibizumab and its potential in the treatment of retinopathy of prematurity","volume":"11","author":"Patel","year":"2019","journal-title":"Eye Brain"},{"key":"10.1016\/j.ophtha.2020.12.028_bib23","doi-asserted-by":"crossref","first-page":"697","DOI":"10.2147\/OPTH.S19555","article-title":"Pharmacokinetics of intravitreal bevacizumab (Avastin\u00ae) in rabbits","volume":"5","author":"Sinapis","year":"2011","journal-title":"Clin Ophthalmol"},{"issue":"5","key":"10.1016\/j.ophtha.2020.12.028_bib24","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.ophtha.2007.01.017","article-title":"Pharmacokinetics of intravitreal bevacizumab (Avastin)","volume":"114","author":"Bakri","year":"2007","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.ophtha.2020.12.028_bib25","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3928\/23258160-20170301-10","article-title":"Reactivation of retinopathy of prematurity three years after treatment with bevacizumab","volume":"48","author":"Hajrasouliha","year":"2017","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"3","key":"10.1016\/j.ophtha.2020.12.028_bib26","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3928\/23258160-20160229-12","article-title":"Very late reactivation of retinopathy of prematurity after monotherapy with intravitreal bevacizumab","volume":"47","author":"Snyder","year":"2016","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"8","key":"10.1016\/j.ophtha.2020.12.028_bib27","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1001\/archophthalmol.2012.592","article-title":"Reactivation of retinopathy of prematurity after bevacizumab injection","volume":"130","author":"Hu","year":"2012","journal-title":"Arch Ophthalmol"},{"issue":"3","key":"10.1016\/j.ophtha.2020.12.028_bib28","first-page":"323","article-title":"Exudative retinopathy and detachment: a late reactivation of retinopathy of prematurity after intravitreal bevacizumab","volume":"17","author":"Ittiara","year":"2013","journal-title":"J\u00a0AAPOS"},{"issue":"5","key":"10.1016\/j.ophtha.2020.12.028_bib29","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.oret.2019.01.016","article-title":"Fluorescein angiography in retinopathy of prematurity: comparison of infants treated with bevacizumab to those with spontaneous regression","volume":"3","author":"Mansukhani","year":"2019","journal-title":"Ophthalmol Retina"},{"issue":"4","key":"10.1016\/j.ophtha.2020.12.028_bib30","doi-asserted-by":"crossref","first-page":"e20160057","DOI":"10.1542\/peds.2016-0057","article-title":"Concerns for development after bevacizumab treatment of ROP","volume":"137","author":"Quinn","year":"2016","journal-title":"Pediatrics"},{"issue":"1","key":"10.1016\/j.ophtha.2020.12.028_bib31","first-page":"2","article-title":"Bevacizumab (Avastin) for retinopathy of prematurity: wrong dose, wrong drug, or both?","volume":"16","author":"Avery","year":"2012","journal-title":"J\u00a0AAPOS"},{"issue":"3","key":"10.1016\/j.ophtha.2020.12.028_bib32","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00417-017-3878-4","article-title":"Changes in systemic vascular endothelial growth factor levels after intravitreal injection of aflibercept in infants with retinopathy of prematurity","volume":"256","author":"Huang","year":"2018","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"9","key":"10.1016\/j.ophtha.2020.12.028_bib33","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1097\/IAE.0000000000000535","article-title":"Plasma concentrations of vascular endothelial growth factor in retinopathy of prematurity after intravitreal bevacizumab injection","volume":"35","author":"Hong","year":"2015","journal-title":"Retina"},{"issue":"4","key":"10.1016\/j.ophtha.2020.12.028_bib34","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1001\/jamaophthalmol.2014.5373","article-title":"Serum levels of vascular endothelial growth factor and related factors after intravitreous bevacizumab injection for retinopathy of prematurity","volume":"133","author":"Wu","year":"2015","journal-title":"JAMA Ophthalmol"},{"issue":"2","key":"10.1016\/j.ophtha.2020.12.028_bib35","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ajo.2011.07.005","article-title":"Serum concentrations of bevacizumab (Avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity","volume":"153","author":"Sato","year":"2012","journal-title":"Am J Ophthalmol"},{"issue":"10208","key":"10.1016\/j.ophtha.2020.12.028_bib36","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(19)31344-3","article-title":"Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial","volume":"394","author":"Stahl","year":"2019","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ophtha.2020.12.028_bib37","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1111\/j.1755-3768.2012.02469.x","article-title":"Serum concentrations of vascular endothelial growth factor in an infant treated with ranibizumab for retinopathy of prematurity","volume":"91","author":"Hoerster","year":"2013","journal-title":"Acta Ophthalmol"},{"issue":"4","key":"10.1016\/j.ophtha.2020.12.028_bib38","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1097\/IAE.0000000000001209","article-title":"Serum vascular endothelial growth factor after bevacizumab or ranibizumab treatment for retinopathy of prematurity","volume":"37","author":"Wu","year":"2017","journal-title":"Retina"},{"issue":"10","key":"10.1016\/j.ophtha.2020.12.028_bib39","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1097\/IAE.0000000000001493","article-title":"Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab, and ranibizumab","volume":"37","author":"Avery","year":"2017","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2020.12.028_bib40","first-page":"1","article-title":"Serum vascular endothelial growth factor levels before and after intravitreous ranibizumab injection for retinopathy of prematurity","volume":"2019","author":"Chen","year":"2019","journal-title":"J\u00a0Ophthalmol"},{"issue":"6","key":"10.1016\/j.ophtha.2020.12.028_bib41","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3928\/23258160-20190605-01","article-title":"Neurodevelopmental outcomes comparing bevacizumab to laser for type 1 ROP","volume":"50","author":"Rodriguez","year":"2019","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"1","key":"10.1016\/j.ophtha.2020.12.028_bib42","first-page":"61","article-title":"Medical and developmental outcomes of bevacizumab versus laser for retinopathy of prematurity","volume":"22","author":"Kennedy","year":"2018","journal-title":"J\u00a0AAPOS"},{"issue":"4","key":"10.1016\/j.ophtha.2020.12.028_bib43","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2015-3218","article-title":"Neurodevelopmental outcomes following bevacizumab injections for retinopathy of prematurity","volume":"137","author":"Morin","year":"2016","journal-title":"Pediatrics"},{"issue":"2","key":"10.1016\/j.ophtha.2020.12.028_bib44","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2018-3537","article-title":"Neurodevelopmental outcomes of preterm infants with retinopathy of prematurity by treatment","volume":"144","author":"Natarajan","year":"2019","journal-title":"Pediatrics"},{"issue":"10","key":"10.1016\/j.ophtha.2020.12.028_bib45","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1016\/j.ophtha.2017.05.007","article-title":"Re: Good: bevacizumab for retinopathy of prematurity: treatment when pathology is embedded in a normally developing vascular system (Ophthalmology. 2016;123:1843\u20131844","volume":"124","author":"Blair","year":"2017","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.ophtha.2020.12.028_bib46","first-page":"2","article-title":"Bevacizumab (Avastin) for retinopathy of prematurity: wrong dose, wrong drug, or both?","volume":"16","author":"Avery","year":"2012","journal-title":"J\u00a0AAPOS"},{"issue":"6","key":"10.1016\/j.ophtha.2020.12.028_bib47","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1001\/jamaophthalmol.2017.1055","article-title":"Assessment of lower doses of intravitreous bevacizumab for retinopathy of prematurity: a phase 1 dosing study","volume":"135","author":"Wallace","year":"2017","journal-title":"JAMA Ophthalmol"},{"issue":"12","key":"10.1016\/j.ophtha.2020.12.028_bib48","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1016\/j.ophtha.2018.05.001","article-title":"A\u00a0dosing study of bevacizumab for retinopathy of prematurity: late recurrences and additional treatments","volume":"125","author":"Wallace","year":"2018","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.ophtha.2020.12.028_bib49","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1001\/jamaophthalmol.2020.0334","article-title":"Short-term outcomes after very low-dose intravitreous bevacizumab for retinopathy of prematurity","volume":"138","author":"Wallace","year":"2020","journal-title":"JAMA Ophthalmol"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642020312057?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642020312057?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T14:10:51Z","timestamp":1758982251000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642020312057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":49,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S0161642020312057"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2020.12.028","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Retinal Detachment after Treatment of Retinopathy of Prematurity with Laser versus Intravitreal Anti\u2013Vascular Endothelial Growth Factor","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2020.12.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}